Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Aclaris Therapeutics, Inc. (ACRS) had Normalized Income after Taxes of $-15.43M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$1.78M |
|
$-15.43M |
|
$1.85M |
|
$-0.07M |
|
$20.18M |
|
$-18.41M |
|
$2.98M |
|
$-15.43M |
|
$-15.43M |
|
$-15.43M |
|
$-15.43M |
|
$-15.43M |
|
|
Normalized Income after Taxes |
$-15.43M |
$-18.41M |
|
$-18.29M |
|
122.58M |
|
122.58M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$104.20M |
|
$0.87M |
|
$84.94M |
|
$189.15M |
|
$26.84M |
|
-- |
|
$30.57M |
|
$57.41M |
|
$131.74M |
|
$131.74M |
|
$131.74M |
|
108.33M |
|
| Cash Flow Statement Financials | |
$-23.05M |
|
$24.17M |
|
$-0.28M |
|
$24.57M |
|
$25.40M |
|
$0.83M |
|
$6.60M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.88 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-4.11% |
|
-1035.90% |
|
-1035.90% |
|
-- |
|
-868.26% |
|
-868.26% |
|
$-23.11M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
9.16 |
|
9.83 |
|
-11.71% |
|
-11.71% |
|
-8.16% |
|
-11.71% |
|
$1.22 |
|
$-0.19 |
|
$-0.19 |
|